What’s Next? Five Things To Look Out For In May
Teva And Viatris Follow Sandoz On Q1; Key Cabometyx Trial Set To Begin
This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.
You may also be interested in...
While Teva and Sandoz have succeeded in having a UK court invalidate a patent and SPC protecting BMS’ Eliquis (apixaban), the originator is planning an appeal against the decision. Meanwhile, further litigation is proceeding over a separate family of Eliquis formulation patents.
Days after Viatris announced a landmark new direction – the divestment of its global biosimilars plus other assets – and its full-year 2021 earnings, company management spoke with a leading investment bank to clarify issues raised by Viatris’ shareholders.
Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.